These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29344876)

  • 41. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
    Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
    BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
    Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK
    BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biosimilars in the European Union: current situation and challenges].
    Wolff-Holz E; Weise M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.
    Mezones-Holguin E; Gamboa-Cardenas RV; Sanchez-Felix G; Chávez-Corrales J; Helguero-Santin LM; Laban Seminario LM; Burela-Prado PA; Castro-Reyes MM; Fiestas F
    Front Pharmacol; 2019; 10():1010. PubMed ID: 31798442
    [No Abstract]   [Full Text] [Related]  

  • 49. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 52. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
    Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.